Evidence map›Paper›PMID 27809840›Full record

ArticleRespiratory research2016

EIF2AK4 mutation as "second hit" in hereditary pulmonary arterial hypertension.

Christina A Eichstaedt, Jie Song, Nicola Benjamin, Satenik Harutyunova, Christine Fischer, Ekkehard Grünig, Katrin Hinderhofer

Abstract read
In one paragraph

Article in Respiratory research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. [Heritable pulmonary arterial hypertension].Innere Medizin (Heidelberg, Germany) · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Reduction ofGenes · 2022
    Article
  18. Review
  19. Review
  20. Genes · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Christina A EichstaedtCenter for Pulmonary Hypertension at the Thoraxclinic, University Hospital Heidelberg, Heidelberg, 69126, Germany.
Jie SongCenter for Pulmonary Hypertension at the Thoraxclinic, University Hospital Heidelberg, Heidelberg, 69126, Germany.
Nicola BenjaminCenter for Pulmonary Hypertension at the Thoraxclinic, University Hospital Heidelberg, Heidelberg, 69126, Germany.
Satenik HarutyunovaCenter for Pulmonary Hypertension at the Thoraxclinic, University Hospital Heidelberg, Heidelberg, 69126, Germany.
Christine FischerInstitute of Human Genetics, Heidelberg University, Im Neuenheimer Feld 366, 69120, Heidelberg, Germany.
Ekkehard GrünigCenter for Pulmonary Hypertension at the Thoraxclinic, University Hospital Heidelberg, Heidelberg, 69126, Germany.
Katrin HinderhoferInstitute of Human Genetics, Heidelberg University, Im Neuenheimer Feld 366, 69120, Heidelberg, Germany. katrin.hinderhofer@med.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMutations in the eukaryotic translation initiation factor 2α kinase 4 (EIF2AK4) gene have recently been identified in recessively inherited veno-occlusive disease. In this study we assessed if EIF2AK4 mutations occur also in a family with autosomal dominantly inherited pulmonary arterial hypertension (HPAH) and incomplete penetrance of bone morphogenic protein receptor 2 (BMPR2) mutations.

methodsClinical examinations in a family with 10 members included physical examination, electrocardiogram, (stress)-echocardiography and lung function. Manifest PAH was confirmed by right heart catheterisation in three affected subjects. Genetic analysis was performed using a new PAH-specific gene panel analysis with next generation sequencing of all known PAH and further candidate genes. Identified variants were confirmed by Sanger sequencing.

resultsAll living family members with manifest HPAH carried two pathogenic heterozygous mutations: a frame shift mutation in the BMPR2 gene and a novel splice site mutation in the EIF2AK4 gene. Two family members who carried the BMPR2 mutation only did not develop manifest HPAH.

conclusionsThis is the first study suggesting that EIF2AK4 can also contribute to autosomal dominantly inherited HPAH. Up to now it has only been identified in a recessive form of HPAH. Only those family members with a co-occurrence of two mutations developed manifest HPAH. Thus, the EIF2AK4 and BMRPR2 mutations support the "second hit" hypothesis explaining the variable penetrance of HPAH in this family. Hence, the assessment of all known PAH genes in families with a known mutation might assist in predictions about the clinical manifestation in so far non-affected mutation carriers.

Indexed as

MutationAdultAged, 80 and overArterial PressureBone Morphogenetic Protein Receptors, Type IIDNA Mutational AnalysisFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHeredityHumansHypertension, PulmonaryMaleMiddle AgedPedigreePenetranceBMPR2 protein, humanBone Morphogenetic Protein Receptors, Type IIEIF2AK4 protein, humanProtein Serine-Threonine KinasesHereditary pulmonary arterial hypertensionNext generation sequencingPulmonary veno-occlusive diseaseTwo-gene model

Identifiers

PMID27809840
PMCPMC5095976

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.